OBJECTIVE
To study clinical manifestations of post-COVID cardiovascular syndrome and effectiveness of combined adjuvant targeted mitochondrial cardiac protective therapy regarding long-term prognosis.
MATERIAL AND METHODS
We analyzed follow-up data using personal data and outpatient cards with inclusion of patients in the «Register of patients with post-COVID cardiovascular disorders». Inclusion criteria were complaints de novo, clinical picture, certain functional and morphological disorders that developed in ≥1 months after COVID-19 and made it possible to diagnose post-COVID cardiovascular syndrome. At the outpatient post-COVID stage, complex adjuvant targeted therapy with mitochondrial cardiac protective drugs was carried out (infusion of phosphocreatine (Neotone) followed by long-term intake of meldonium).
RESULTS
In 24% of people who have been infected with SARS-CoV-2, some of the above-mentioned clinical and functional-morphological disorders were noted. In post-COVID period, regression of clinical symptoms and prognosis of heart failure depended on severity of clinical manifestations and treatment. Reduced myocardial perfusion and contractility on the background of peroxidation and inhibition of antioxidant enzymes, hemorheological syndrome were indications for long-term cardiac protective therapy. Complex therapy with phosphocreatine infusion (Neotone) and subsequent intake of meldonium resulted positive clinical dynamics. Indeed, there were better myocardial contractility with increase in ejection fraction, relief of palpitation paroxysms and heart failure, improvement in general well-being with a tendency to normalizing the indicators of peroxidation, antioxidant enzymes and hemorheological parameters after 10 days of therapy with Neotone. After 2 months, therapy with meldonium was followed by regression of clinical manifestations, heart rhythm disturbances, restoration of myocardial contractility and ejection fraction increase up to 65%, improvement of myocardial perfusion, normalization of lipid peroxidation, antioxidant enzymes and hemorheology.
CONCLUSION
Patients with post-COVID cardiovascular syndrome require a personalized approach. Along with symptomatic therapy, combined adjuvant targeted mitochondrial cardiac protective therapy should be applied. Infusion of phosphocreatine (Neotone) and meldonium are preferred.
